Revenio Group Oyj - Financial Calendar

Revenio Group Corporation: Financial reporting and annual general meeting in 2017

Revenio Group Corporation, Stock Exchange Release, December 19, 2016 at 11.00


REVENIO GROUP'S FINANCIAL REPORTING AND ANNUAL GENERAL MEETING IN 2017


During 2017, Revenio Group Corporation will publish the following financial
reports:


- Financial Statements bulletin in regard to 2016 on Thursday, February 16, 2017

- Interim Report 1-3/2017 on Thursday, April 20, 2017

- Interim Report 1-6/2017 on Monday, August 7, 2017

- Interim Report 1-9/2017 on Thursday, October 26, 2017



Due to an amendment in the Securities Market Act, which came into force on 26
November 2015, Revenio will publish the descriptive sections of its interim
reports for 1-3/2017 and 1-9/2017 in a more concise form than before. The table
sections will be reported in accordance with previous practices.

The Annual General Meeting is planned to be hold on Wednesday, March 22, 2017.
The Board of Directors will give a separate notice of the Annual General Meeting
later.

A shareholder, who wishes to place an item on the agenda of the Annual General
Meeting, shall submit the request in writing to the company's Board of Directors
by February 3, 2017. Such requests including the reasoning or a resolution
proposal can be submitted to the address: Revenio Group Corporation / Board of
Directors, Äyritie 22, FI-01510 Vantaa, Finland.

The Annual Report for 2016 will be published on Group's website www.revenio.fi
during week 9 in 2017.



Revenio Group Oyj
Olli-Pekka Salovaara
CEO


For further information, please contact:

President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi


The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin
for continuing operations standing at 28.4%. Revenio Group Corporation is listed
on Nasdaq Helsinki.



[]